Maria Sidorova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8397493/publications.pdf

Version: 2024-02-01

623734 677142 64 653 14 22 citations g-index h-index papers 86 86 86 549 citing authors docs citations times ranked all docs

#	Article	IF	Citations
1	212Pb: Production Approaches and Targeted Therapy Applications. Pharmaceutics, 2022, 14, 189.	4.5	26
2	Chimeric Agonist of Galanin Receptor GALR2 Reduces Heart Damage in Rats with Streptozotocin-Induced Diabetes. Biochemistry (Moscow), 2022, 87, 346-355.	1.5	2
3	The Crystal Structure Elucidation of a Tetrapeptide Analog of Somatostatin DOTA-Phe-D-Trp-Lys-Thr-OMe. Crystals, 2022, 12, 12.	2.2	1
4	Exogenous Galanin Reduces Hyperglycemia and Myocardial Metabolic Disorders Induced by Streptozotocin in Rats. International Journal of Peptide Research and Therapeutics, 2022, 28, .	1.9	1
5	Galanin Peptides Alleviate Myocardial Ischemia/Reperfusion Injury by Reducing Reactive Oxygen Species Formation. International Journal of Peptide Research and Therapeutics, 2021, 27, 2039-2048.	1.9	4
6	Đ"Đ¾Đ°Đ»Đ¸Đ½Đ¸Ñ‡ĐµÑĐ°Đ¾Đµ иÑ Ñ леĐƊ¾Đ2Đ°Đ½Đ¸Đµ Ñ"Đ°Ñ€Đ¼Đ°Đ°Đ¾Đ°Đ¸Đ½ĐµÑ,иаи иĐ)¹⁄2 ∂. 3Ñ€Ð	°Đ��Đ¾Đ½E
7	Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2021, 15, 274-280.	0.4	3
8	Optimal Method for Disulfide Bond Closure in the Synthesis of Atosibanâ€"Antagonist of Oxytocin Receptors. Russian Journal of Bioorganic Chemistry, 2021, 47, 1241-1248.	1.0	4
9	Optimization of the Solid Phase Synthesis of the Ingramon Peptide Antagonist of the Human Monocyte Chemoattractant Protein 1 (MCP-1). Russian Journal of Bioorganic Chemistry, 2020, 46, 520-529.	1.0	O
10	New PAR1 Agonist Peptide Demonstrates Protective Action in a Mouse Model of Photothrombosis-Induced Brain Ischemia. Frontiers in Neuroscience, 2020, 14, 335.	2.8	1
11	Convergent Synthesis of the Rat Galanin and Study of Its Biological Activity. Russian Journal of Bioorganic Chemistry, 2020, 46, 32-42.	1.0	5
12	[MeArg1, NLe10]-apelin-12: Optimization of solid-phase synthesis and evaluation of biological properties in vitro and in vivo. Peptides, 2020, 129, 170320.	2.4	6
13	Galanin and its N-terminal fragments reduce acute myocardial infarction in rats. Peptides, 2019, 111, 127-131.	2.4	13
14	Galanin receptors activation modulates myocardial metabolic and antioxidant responses to ischaemia/reperfusion stress. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 1174-1182.	1.9	8
15	Fragments of the Galanin Peptide and Their Synthetic Analogues with the Cardioprotective Effect. Russian Journal of Bioorganic Chemistry, 2019, 45, 353-360.	1.0	2
16	Synthesis and Antitumor Activity of Conjugates Based on the Phe-D-Trp-Lys-Thr Peptide Fragment of Somatostatin. Russian Journal of Bioorganic Chemistry, 2019, 45, 248-252.	1.0	4
17	Protective Action of a Modified Galanin Fragment in Rats with Doxorubicin-Induced Heart Failure. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2019, 13, 167-172.	0.4	0
18	Optimization of the Synthesis of an Apelin-12 Structural Analog and the NMR Study of Its Stability in Human Plasma. Russian Journal of Bioorganic Chemistry, 2019, 45, 18-26.	1.0	1

#	Article	IF	Citations
19	Cardiometabolic Efficacy and Toxicological Evaluation of a Pharmacological Galanin Receptor Agonist. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2019, 13, 349-356.	0.4	O
20	Galanin/GalR1-3 system: A promising therapeutic target for myocardial ischemia/reperfusion injury. Biomedicine and Pharmacotherapy, 2019, 109, 1556-1562.	5.6	23
21	Protective Effects of a Novel Agonist of Galanin Receptors Against Doxorubicin-Induced Cardiotoxicity in Rats. Cardiovascular Toxicology, 2019, 19, 136-146.	2.7	14
22	Synthesis and Infarction-Limiting Properties of Peptide Agonists of Opioid Receptors. Pharmaceutical Chemistry Journal, 2018, 52, 291-293.	0.8	0
23	Effects of Deltorphin II and Its Retroenantio Analog on Cardiac Tolerance to Ischemia and Reperfusion. Bulletin of Experimental Biology and Medicine, 2017, 162, 306-309.	0.8	4
24	Solid-phase fragment condensation for synthesis of peptides from the immunodominant sequence of \hat{l}^21 -adrenoreceptor. Russian Journal of Bioorganic Chemistry, 2017, 43, 351-358.	1.0	1
25	Cysteine-Containing Peptides Stimulate Monocyte Migration through NADPH-Oxidase Activation. Bulletin of Experimental Biology and Medicine, 2017, 163, 203-205.	0.8	1
26	Impact of Atherosclerosis- and Diabetes-Related Dicarbonyls on Vascular Endothelial Permeability: A Comparative Assessment. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	4.0	12
27	Myocardial protection from ischemia/reperfusion injury by exogenous galanin fragment. Oncotarget, 2017, 8, 21241-21252.	1.8	38
28	Cardioprotective properties of N-terminal galanin fragment (2-15) in experimental ischemia/reperfusion injury. Oncotarget, 2017, 8, 101659-101671.	1.8	28
29	Design of peptidase-resistant peptide inhibitors of myosin light chain kinase. Journal of Peptide Science, 2016, 22, 673-681.	1.4	5
30	Ingramon, a Peptide Inhibitor of MCP-1 Chemokine, Reduces Migration of Blood Monocytes Stimulated by Glioma-Conditioned Medium. Bulletin of Experimental Biology and Medicine, 2016, 160, 480-482.	0.8	6
31	Peptide-agonist of protease-activated receptor (PAR1) stimulates keratinocyte proliferation and epithelial layer wound healing similarly to activated protein C. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2015, 9, 199-204.	0.4	1
32	Synthetic conformational antigen which simulates the extracellular part of the M2-muscarinic receptor: interaction with blood sera of patients suffering from idiopathic arrhythmias. Russian Journal of Bioorganic Chemistry, 2013, 39, 252-258.	1.0	0
33	Effects of structural analogues of apelin-12 in acute myocardial infarction in rats. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, 198.	0.4	28
34	Suppression of vascular endothelium hyperpermeability by cell-permeating peptide inhibitors of myosin light chain kinase. Biophysics (Russian Federation), 2012, 57, 587-591.	0.7	1
35	Peptide fragment 29–40 of amino acid sequence of monocyte chemoattractant protein-1 (MCP-1) stimulates monocyte migration in vivo and facilitates wound healing. Doklady Biological Sciences, 2012, 446, 327-330.	0.6	3
36	Limitation of myocardial infarction by a structural analog of the peptide apelin-12. Doklady Biological Sciences, 2012, 443, 65-67.	0.6	7

#	Article	IF	CITATIONS
37	The role of inhibition of NO formation in the metabolic recovery of ischemic rat heart by apelin-12. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2012, 6, 55-60.	0.4	O
38	Inhibitor of inflammation, peptide fragment (65–76) of monocyte chemotactic protein-1 (MCP-1), inhibits binding of MCP-1 to heparin. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2011, 5, 29-36.	0.6	0
39	In Vivo Reduction of Reperfusion Injury to the Heart with Apelin-12 Peptide in Rats. Bulletin of Experimental Biology and Medicine, 2011, 152, 79-82.	0.8	20
40	Synthetic peptide fragment (65–76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting. Inflammation Research, 2011, 60, 955-964.	4.0	15
41	Preparation of affinity sorbents with immobilized synthetic ligands for therapeutic apheresis. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2010, 4, 303-307.	0.4	6
42	Novel peptide inhibitors of myosin light chain kinase suppress the hyperpermeability of vascular endothelium. Biophysics (Russian Federation), 2010, 55, 926-930.	0.7	0
43	Effect of the C-terminal domain peptide fragment (65–76) of monocytic chemotactic protein-1 (MCP-1) on the interaction between MCP-1 and heparin. Doklady Biological Sciences, 2010, 433, 289-292.	0.6	6
44	BILINEAR R-PARITY VIOLATION IN RARE MESON DECAYS., 2009,,.		0
45	Effects of synthetic monocyte chemotactic protein-1 fragment 65–76 on neointima formation after carotid artery balloon injury in rats. Neuroscience and Behavioral Physiology, 2009, 39, 153-159.	0.4	4
46	The peptide analogue of MCP-1 65–76 sequence is an inhibitor of inflammationThis paper is one of a selection of papers published in this Special Issue, entitled The Cellular and Molecular Basis of Cardiovascular Dysfunction, Dhalla 70th Birthday Tribute Canadian Journal of Physiology and Pharmacology, 2007, 85, 332-340.	1.4	8
47	Rare meson decay in supersymmetric theory with nonconservation of R-parity. Moscow University Physics Bulletin (English Translation of Vestnik Moskovskogo Universiteta, Fizika), 2007, 62, 6-11.	0.4	O
48	The synthesis of immunomodulating peptide alloferon, the active principle of antiviral drug allokine-alpha. Russian Journal of Bioorganic Chemistry, 2006, 32, 136-145.	1.0	0
49	Peptide fragment 66–77 of monocyte chemoattractant protein 1 and its retro-enantio analogue inhibit the migration of cells in vitro and in vivo. Russian Journal of Bioorganic Chemistry, 2006, 32, 146-153.	1.0	1
50	Inhibition of migration of monocytes and granulocytes in vivo by the peptide corresponding to sequence 65‰76 of monocyte chemotactic protein-1 (MCP-1). Doklady Biochemistry and Biophysics, 2006, 411, 339-341.	0.9	3
51	Majorana neutrinos in rare meson decays. Physics of Atomic Nuclei, 2006, 69, 475-484.	0.4	3
52	RARE SEMILEPTONIC MESON DECAYS IN R-PARITY VIOLATING MSSM. , 2006, , .		0
53	The Peptide of Sequence 66–77 of Monocytic Chemotactic Protein (MCP-1) Inhibits Inflammation in Experimental Animals. Doklady Biological Sciences, 2005, 404, 402-405.	0.6	6
54	Novel Phosphospecific Antibodies for Monitoring Phosphorylation of Proteins Encoded by the Myosin Light Chain Kinase Genetic Locus. Biochemistry (Moscow), 2004, 69, 789-798.	1.5	3

#	Article	IF	CITATIONS
55	Hydrogen peroxide for disulfide bridge formation in methionine-containing peptides. , 2000, 6, 208-216.		5
56	Effect of synthetic peptide fragments of \hat{l}^2 2-glycoprotein-l on the binding of antiphospholipid antibodies to cardiolipin-glycoprotein-l on the binding of antiphospholipid antibodies to cardiolipin. Bulletin of Experimental Biology and Medicine, 1999, 127, 44-46.	0.8	0
57	Identification of an atypical lipoprotein-binding protein from human aortic smooth muscle as T-cadherin. FEBS Letters, 1998, 421, 208-212.	2.8	43
58	Some peculiarities of synthesis of cysteine-containing peptides. Russian Chemical Reviews, 1998, 67, 545-562.	6.5	18
59	Comparative evaluation of different methods for disulfide bond formation in synthesis of the HIVâ€2 antigenic determinant. Chemical Biology and Drug Design, 1997, 49, 52-58.	1.1	30
60	Solid-phase synthesis and purification of \hat{l}^2 -amyloid (1-42). Mendeleev Communications, 1996, 6, 232-235.	1.6	1
61	Effect of synthetic fragments of HIV protein immunodominant sites on human neutrophil oxygen metabolism. Bulletin of Experimental Biology and Medicine, 1993, 115, 188-190.	0.8	1
62	Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein. Virology, 1993, 194, 294-301.	2.4	38
63	CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments. Molecular Immunology, 1993, 30, 993-1001.	2.2	21
64	Investigation of Human Immunodeficiency Virus Fusion Peptides. Analysis of Interrelations Between Their Structure and Function. AIDS Research and Human Retroviruses, 1992, 8, 9-18.	1,1	54